Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T75256
|
||||
Former ID |
TTDI02120
|
||||
Target Name |
MART-1 melanoma antigen
|
||||
Gene Name |
MLANA
|
||||
Synonyms |
Antigen LB39AA; Antigen SK29AA; MART1; Melanoma antigen recognized by Tcells 1; Protein MelanA; MLANA
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Melanoma [ICD9: 172; ICD10: C43] | ||||
Function |
Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes.
|
||||
BioChemical Class |
Melanoma antigen recognized by T cells 1
|
||||
UniProt ID | |||||
Sequence |
MPREDAHFIYGYPKKGHGHSYTTAEEAAGIGILTVILGVLLLIGCWYCRRRNGYRALMDK
SLHVGTQCALTRRCPQEGFDHRDSKVSLQEKNCEPVVPNAPPAYEKLSAEQSPPPYSP |
||||
Drugs and Mode of Action | |||||
Drug(s) | Melanoma vaccine | Drug Info | Phase 3 | Melanoma | [521514] |
Multi-epitope peptide melanoma vaccine | Drug Info | Phase 3 | Melanoma | [521514] | |
MKC-1106-MT | Drug Info | Phase 2 | Melanoma | [522880] | |
Polynoma-1 | Drug Info | Phase 2 | Melanoma | [551529] | |
Melanoma vaccine | Drug Info | Discontinued in Phase 2 | Melanoma | [547218] | |
F-50040 | Drug Info | Discontinued in Phase 1 | Melanoma | [547414] | |
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
References | |||||
Ref 521514 | ClinicalTrials.gov (NCT00036816) Vaccine Therapy in Treating Patients With Melanoma of the Eye. U.S. National Institutes of Health. | ||||
Ref 522880 | ClinicalTrials.gov (NCT01026051) Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma. U.S. National Institutes of Health. | ||||
Ref 547218 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014153) | ||||
Ref 526271 | Stability and CTL-activity of P40/ELA melanoma vaccine candidate. Biologicals. 2001 Sep-Dec;29(3-4):293-8. | ||||
Ref 531162 | Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58. | ||||
Ref 544270 | Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.